You are here

Potential Hepatitis Delta Virus Infection Treatment Gets Orphan Drug Designation

Pegylated interferon lambda 1a stimulates immune responses

The FDA has granted orphan drug status to pegylated interferon lambda 1a (Lambda, Eiger Bio, Inc.) as a potential treatment for chronic hepatitis delta virus (HDV) infection.

Hepatitis delta is caused by infection with HDV and is considered to be one of the most severe forms of viral hepatitis in humans. Hepatitis delta occurs only as a coinfection in individuals harboring hepatitis B virus (HBV). Hepatitis delta leads to more severe liver disease than HBV alone and is associated with accelerated liver fibrosis, liver cancer, and liver failure. Hepatitis delta is a disease with a significant impact on global health; it may affect as many as 15–20 million people worldwide. The prevalence of HDV varies among different parts of the world. Globally, HDV infection is reported to be present in approximately 4.3% to 5.7% of chronic hepatitis B carriers. The prevalence of HDV in patients infected with chronic HBV is even higher in certain regions, including parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa, the Middle East, and South America, with an HDV prevalence as high as 60% being reported in HBV-infected patients in Mongolia and Pakistan.

Pegylated interferon lambda 1a is a late-stage, first-in-class, type III interferon (IFN) that stimulates immune responses critical for the development of host protection during viral infections. Pegylated interferon lambda 1a targets type III IFN receptors, which are distinct from the type I IFN receptors targeted by IFN alfa. These type III receptors are highly expressed on hepatocytes with limited expression on hematopoietic and central nervous system cells, which may reduce off-target effects and improve tolerability of pegylated interferon lambda 1a. Although it does not use the IFN alfa receptor, signaling through either the IFN lambda or IFN alfa receptor complexes results in the activation of the same Jak-STAT signal transduction cascade.

Eiger licensed worldwide rights to Lambda from Bristol-Myers Squibb in April 2016. Pegylated interferon lambda 1a has been administered in HBV and hepatitis C virus clinical trials involving more than 3,000 patients, but has not yet been approved for any indication.

Source: Eiger; September 5, 2017.

More Headlines

New combo is a maintenance treatment for virologically suppressed HIV-1
Researchers find opioid-agonist treatment saves lives and money compared with detox
Tirasemtiv did not differentiate itself from placebo in phase 3 study
Instead of targeting CD19 on the surface of cancer cells, new approach targets CD22
Four in 10 U.S. cases and deaths are linked to risk factors we can change
Approach could help slow growth of antibiotic-resistant bacteria
Needle length and dose target patients weighing 16.5 to 33 pounds
Five sepsis deaths had been reported in late-phase trials
Patients can avoid long drives to distant specialists